\BOOKMARK [0][-]{chapter.1}{Literature Review I}{}% 1
\BOOKMARK [0][-]{chapter.2}{Literature Review II}{}% 2
\BOOKMARK [1][-]{section.2.1}{Antipsychotic pharmacogenomics}{chapter.2}% 3
\BOOKMARK [2][-]{subsection.2.1.1}{Background}{section.2.1}% 4
\BOOKMARK [1][-]{section.2.2}{Antipsychotic medications}{chapter.2}% 5
\BOOKMARK [2][-]{subsection.2.2.1}{First-generation antipsychotics}{section.2.2}% 6
\BOOKMARK [2][-]{subsection.2.2.2}{Second-generation antipsychotics}{section.2.2}% 7
\BOOKMARK [1][-]{section.2.3}{Antipsychotics: Mechanism of action}{chapter.2}% 8
\BOOKMARK [2][-]{subsection.2.3.1}{Role of dopamine D2 receptor blockage}{section.2.3}% 9
\BOOKMARK [2][-]{subsection.2.3.2}{Role of Non-D2 Receptor blockage}{section.2.3}% 10
\BOOKMARK [2][-]{subsection.2.3.3}{Preferential Limbic dopamine D2 receptor blockage}{section.2.3}% 11
\BOOKMARK [1][-]{section.2.4}{Treatment response to antipsychotics medication}{chapter.2}% 12
\BOOKMARK [2][-]{subsection.2.4.1}{Scales for assessing response to antipsychotics}{section.2.4}% 13
\BOOKMARK [2][-]{subsection.2.4.2}{Factors influencing antipsychotic response}{section.2.4}% 14
\BOOKMARK [1][-]{section.2.5}{Pharmacogenetics and pharmacogenomics of antipsychotic treatment}{chapter.2}% 15
\BOOKMARK [2][-]{subsection.2.5.1}{Candidate gene studies}{section.2.5}% 16
\BOOKMARK [2][-]{subsection.2.5.2}{Genome-wide association studies}{section.2.5}% 17
\BOOKMARK [2][-]{subsection.2.5.3}{Next-generation sequencing}{section.2.5}% 18
\BOOKMARK [1][-]{section.2.6}{Difficulties and challenges in pharmacogenomic studies}{chapter.2}% 19
\BOOKMARK [2][-]{subsection.2.6.1}{Methodological issues}{section.2.6}% 20
\BOOKMARK [2][-]{subsection.2.6.2}{Statistical issues}{section.2.6}% 21
